assessing-drug-interactions

name	assessing-drug-interactions
description	Identifies clinically significant drug-drug, drug-food, and drug-disease interactions with severity grading and management recommendations. Use when checking drug interactions, evaluating polypharmacy risks, or managing medication combinations.
tags	["assessment","pharmacy","risk","clinical"]
metadata	{"author":"casemark","practice_areas":["Clinical Pharmacy","Pharmacy"],"document_types":["Assessment Report"],"skill_modes":["Assessment"]}

Assessing Drug Interactions

Identifies clinically significant drug-drug, drug-food, and drug-disease interactions with severity grading and management recommendations.

Why This Skill Exists

Drug interactions account for approximately 3-5% of all in-hospital medication errors and are a leading cause of preventable adverse drug events. The clinical consequences range from therapeutic failure (e.g., reduced efficacy of oral contraceptives with rifampin) to life-threatening toxicity (e.g., serotonin syndrome from SSRI-MAOI combinations, QT prolongation from concurrent QTc-prolonging agents). Polypharmacy patients—particularly elderly individuals on 5+ medications—face exponentially increasing interaction risk.

Pharmacists are the final safety net before a drug reaches the patient. Robust interaction assessment requires knowledge of cytochrome P450 enzyme systems (CYP3A4, CYP2D6, CYP2C19, CYP1A2), P-glycoprotein transport, renal tubular secretion competition, and pharmacodynamic synergism/antagonism. Regulatory bodies including the Joint Commission (NPSG.03.05.01) and CMS Conditions of Participation mandate prospective drug utilization review for every dispensed prescription. Failure to identify a clinically significant interaction constitutes a deviation from the standard of care and carries malpractice liability.

---

Checkpoint A: Pre-Draft Intake (Mandatory)

1. What is the complete active medication list, including OTC, herbals, and supplements? (Default: request MAR or pharmacy profile)
2. What is the patient's age, sex, weight, and relevant organ function (hepatic/renal)? (Default: assume normal organ function if unspecified, flag as [VERIFY])
3. What is the clinical indication for each medication under review? (Default: pull from problem list)
4. Is there a specific new medication being added, or is this a comprehensive polypharmacy review? (Default: comprehensive)
5. What interaction databases are available? (Default: Lexicomp, Clinical Pharmacology, Micromedex)
6. Are there known patient-specific sensitivities or prior ADR history? (Default: none documented)
7. What is the care setting—inpatient, outpatient, or transitions of care? (Default: inpatient)
8. Is pharmacogenomic data available (CYP2D6, CYP2C19 phenotype)? (Default: not available)

Documents to Request

• Current medication administration record (MAR) or e-prescribing profile
• Recent lab values: INR, serum drug levels, LFTs, SCr/BUN, electrolytes (K+, Mg2+, QTc if relevant)
• Pharmacogenomic panel results if available
• Allergy and ADR history
• Problem list with active diagnoses
• Recent ECG if QTc-prolonging agents are involved

---

Step 1: Catalog All Active Substances

List every active pharmaceutical ingredient the patient is receiving. Include:

• Prescription medications with dose, route, frequency
• OTC medications (NSAIDs, antihistamines, PPIs)
• Herbal/dietary supplements (St. John's wort, grapefruit, ginkgo)
• PRN medications and recent as-needed use dates

Assign each substance its primary metabolic pathway:

CYP Enzyme	Common Substrates	Common Inhibitors	Common Inducers
CYP3A4	Simvastatin, cyclosporine, midazolam	Ketoconazole, clarithromycin, ritonavir	Rifampin, phenytoin, carbamazepine
CYP2D6	Codeine, metoprolol, fluoxetine	Paroxetine, fluoxetine, bupropion	Not significantly inducible
CYP2C19	Clopidogrel, omeprazole, voriconazole	Fluconazole, fluvoxamine, omeprazole	Rifampin, St. John's wort
CYP2C9	Warfarin, phenytoin, losartan	Fluconazole, amiodarone, metronidazole	Rifampin
CYP1A2	Theophylline, clozapine, caffeine	Fluvoxamine, ciprofloxacin	Smoking, omeprazole (minor)

---

Step 2: Screen and Classify Interactions

Run each combination through at least two independent drug interaction databases. Classify each identified interaction:

Severity Grading (use Lexicomp/Micromedex concordance):

• Contraindicated (X): Combination must not be used. Examples: linezolid + serotonergic agents, simvastatin + itraconazole
• Major (D): Modify therapy; combination may cause serious harm. Examples: warfarin + fluconazole, methotrexate + trimethoprim
• Moderate (C): Monitor therapy; adjust dose or timing as needed. Examples: ACE inhibitors + potassium supplements, digoxin + amiodarone
• Minor (B): No action needed for most patients. Examples: antacids + iron timing

Mechanism Classification:

• Pharmacokinetic: absorption, distribution, metabolism (CYP inhibition/induction), elimination
• Pharmacodynamic: additive, synergistic, or antagonistic effects at receptor/organ level
• Mixed: both PK and PD components

---

Step 3: Evaluate Clinical Significance

Not all flagged interactions require intervention. Assess clinical significance by:

1. Therapeutic index: Narrow therapeutic index drugs (warfarin, digoxin, lithium, phenytoin, theophylline, aminoglycosides) demand higher vigilance
2. Onset timing: Immediate (within 24 hours) vs. delayed (days to weeks, e.g., enzyme induction)
3. Dose-dependency: Some interactions only manifest at higher doses (e.g., QTc prolongation)
4. Patient vulnerability: Age >65, hepatic/renal impairment, genetic polymorphisms increase risk
5. Duration of co-administration: Short-term concurrent use may not reach steady-state interaction
6. Evidence quality: Case reports vs. controlled studies vs. mechanistic extrapolation

---

Step 4: Formulate Management Recommendations

For each clinically significant interaction, provide one of:

• Avoid combination: Recommend specific therapeutic alternative
• Dose adjustment: Specify percentage reduction or new target dose
• Enhanced monitoring: Define parameters (lab values, vital signs, symptoms) and frequency
• Timing separation: Specify administration interval (e.g., fluoroquinolones and cations separated by 2 hours)
• Patient counseling points: Symptoms to watch for and when to seek care

Document the supporting evidence level for each recommendation (clinical guideline, pharmacokinetic study, case series, or mechanistic rationale).

---

Step 5: Generate Interaction Assessment Report

Structure the final output as:

1. Patient identifier and date of review
2. Interaction summary table: Drug pair | Severity | Mechanism | Recommendation | Evidence level
3. Detailed narrative for each Major/Contraindicated interaction
4. Monitoring plan with timeline
5. Medications cleared with no significant interactions
6. Pharmacist attestation and limitations statement

---

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Were all active medications including OTC/herbals accounted for in the screen?
2. Do severity ratings from the two databases agree, and were discrepancies resolved?
3. Has each Major or Contraindicated interaction received a specific management recommendation?
4. Are monitoring parameters clearly defined with lab/timing specifics?
5. Have narrow therapeutic index drugs been individually addressed regardless of screen results?

---

Quality Audit

• Complete medication list was obtained and documented
• At least two independent interaction databases were queried
• Each interaction is classified by severity (X, D, C, B) and mechanism (PK, PD, mixed)
• Contraindicated combinations have clear stop-or-substitute directives
• Narrow therapeutic index drugs were individually reviewed
• CYP enzyme pathways are cited for pharmacokinetic interactions
• Pharmacogenomic status is addressed if data available
• Monitoring parameters include specific lab values, intervals, and escalation triggers
• Timing-sensitive interactions include administration scheduling guidance
• Patient-specific risk factors (age, organ function) are factored into significance assessment
• Evidence level is cited for each recommendation
• Report includes limitations and [VERIFY] flags for missing data
• QTc-prolonging combinations are flagged with ECG monitoring recommendation

---

Guidelines

• Always screen against at least two interaction databases to reduce false negatives
• Classify by mechanism (PK vs. PD) before grading severity—mechanism informs management
• Prioritize narrow therapeutic index drugs for detailed review regardless of initial screen
• Never dismiss a contraindicated (X-rated) interaction without prescriber communication and documentation
• Include OTC and herbal products; St. John's wort is a potent CYP3A4/P-gp inducer often missed
• Factor in pharmacogenomic status when available—CYP2D6 poor metabolizers face amplified inhibition interactions
• Document clinical rationale when accepting a moderate interaction with monitoring rather than avoidance
• Time-stamp all assessments; interaction profiles change when medications are added or discontinued